Aripiprazole lauroxil

Drug Profile

Aripiprazole lauroxil

Alternative Names: ALNCD; ALKS-9070; ALKS-9072; Aripiprazole Lauroxil NanoCrystal® Dispersion; ARISTADA

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alkermes
  • Developer Alkermes plc
  • Class Antipsychotics; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 16 Nov 2017 FDA assigns PDUFA action date of 30/06/2018 for Aripiprazole Lauroxil NanoCrystal® Dispersion for Schizophrenia (New delivery system)
  • 16 Nov 2017 The US FDA accepts NDA for Aripiprazole Lauroxil NanoCrystal® Dispersion for Schizophrenia (New delivery system) for review
  • 26 Oct 2017 Alkermes plans a phase IIIb trial for Schizophrenia in November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top